In conclusion, we identified CHA79 as a GLP-1R-activating compound, effective in attenuating MG neurotoxicity with neurotrophic, antioxidant and glyoxalase pathway-improving capabilities. This evidence concerns the gene GLP1R and myasthenia gravis.